References

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

10.1155/2005/269076 · 2005 · External reference

The natural history of adult Crohn’s disease in population-based cohorts

10.1038/ajg.2009.579 · 2010 · External reference

ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment

10.1093/ecco-jcc/jjae089 · 2024 · External reference

Natural history, diagnosis and treatment approach to fibrostenosing Crohn’s disease

10.1177/2050640620901960 · 2020 · External reference

Ten-year experience of strictureplasty for obstructive Crohn’s disease

10.1002/bjs.1800760407 · 1989 · External reference

The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations

10.1016/j.crohns.2009.09.009 · 2010 · External reference

Bowel damage as assessed by the Lémann index is reversible on anti-TNF therapy for Crohn’s disease

10.1093/ecco-jcc/jjv080 · 2015 · External reference

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial

10.1016/s0016-5085(99)70005-3 · 1999 · External reference

Infliximab treatment for symptomatic Crohn’s disease strictures

10.1111/j.1365-2036.2008.03887.x · 2009 · External reference

ECCO guidelines on therapeutics in Crohn’s disease: medical treatment

10.1093/ecco-jcc/jjae091 · 2024 · External reference

Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study

10.1111/j.1365-2036.2012.05100.x · 2012 · External reference

Assessment of activity and severity of inflammatory bowel disease in cross-sectional imaging techniques: a systematic review

10.1093/ecco-jcc/jjaf023 · 2025 · External reference

Rayyan-a web and mobile app for systematic reviews

10.1186/s13643-016-0384-4 · 2016 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]

10.26633/rpsp.2022.112 · 2022 · External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

10.1136/bmj.i4919 · 2016 · External reference

Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

10.1136/gutjnl-2016-312581 · 2018 · External reference

Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn’s disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial

10.1016/s2468-1253(21)00393-9 · 2022 · External reference

Crohn’s disease stricture response to treatment assessed with magnetic resonance imaging and intestinal ultrasound: STRIDENT randomized trial

10.1093/ibd/izaf073 · 2025 · External reference

Stricture dynamics and prognosis during biologic therapy in ileal Crohn’s disease: a real-world cohort

10.1093/ibd/izag0122026 · External reference

Outcomes of passable and non-passable strictures in clinical trials of Crohn’s disease: a post-hoc analysis

10.1093/ecco-jcc/jjab045 · 2021 · External reference

Effect of infliximab on small bowel stenoses in patients with Crohn’s disease

10.3748/wjg.14.1885 · 2008 · External reference

Serial changes in intestinal stenotic stiffness in patients with Crohn’s disease treated with biologics: a pilot study using ultrasound shear wave elastography

10.5152/tjg.2023.22768 · 2023 · External reference

Infliximab, azathioprine, or combination therapy for Crohn’s disease

10.1056/nejmoa0904492 · 2010 · External reference

Ustekinumab as induction and maintenance therapy for Crohn’s disease

10.1056/nejmoa1602773 · 2016 · External reference

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study

10.1016/s0140-6736(18)32196-2 · 2019 · External reference

A prospective 52 week mucosal healing assessment of small bowel Crohn’s disease as detected by capsule endoscopy

10.1016/j.crohns.2014.09.005 · 2014 · External reference

Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study

2007 · External reference

[Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn’s disease]

10.1055/s-2003-36677 · 2003 · External reference

ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: part 1

10.1093/ecco-jcc/jjaf106 · 2025 · External reference

ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: part 2

10.1093/ecco-jcc/jjaf107 · 2025 · External reference

10.1093/ecco-jcc/jjaf231.558

10.1093/ecco-jcc/jjaf231.558 · 2026 · External reference